Final Report (all chapters)

2.5 Bibliography
American Academy of Pediatrics, and Committee on Drugs and Committee on Bioethics.
"Considerations Related to the Use of Recombinant Human Growth Hormone in
Children." Pediatrics 99, no. 1 (1997): 122-29.
Center for Drug Evaluation and Research, Food and Drug Administration. "Endocrinologic and
Metabolic Drugs Advisory Committee Meeting." edited by Food and Drug
Administration Department of Health and Human Services, October 7, 2003.
Croley, Steven P., and William F. Funk. "The Federal Advisory Committee Act and Good
Governance." Yale Journal on Regulation 14 (1997): 451-539.
Elliott, Carl. Better Than Well: American Medicine Meets the American Dream. New York:
W.W. Norton & Company, 2003.
Guyda, Harvey J. "Four Decades of Growth Hormone Therapy for Short Children: What Have
We Achieved?" The Journal of Clinical Endocrinology & Metabolism 84, no. 12 (1999):
4307-16.
Health Technology Advisory Committee, Minnesota Department of Health. The Use of Growth
Hormone for Children with Idiopathic Short Stature Minnesota Department of Health,
2000 [cited April 24, 2006]. Available from http://www.health.state.mn.us/htac/hgh.htm.
Kramer, Peter D. Listening to Prozac: The Landmark Book About Antidepressants and the
Remaking of the Self. New York: Penguin Books, 1997.
Lipset, Seymour Martin. American Exceptionalism: A Double-Edged Sword. New York: W.W.
Norton & Company, 1996.
Schwartz, Peter H. "Genetic Breakthroughs and the Limits of Medicine: Short Stature, Growth
Hormone, and the Idea of Dysfunction." St. Thomas Law Review 13 (2001): 965-78.
Sunstein, Cass, and Edna Ullmann-Margalit. "Second-Order Decisions." Ethics 110 (1999): 5-
31.
Winner, Langdon. "Technology Today: Utopia or Dystopia?" Social Research 64, no. 3 (1997):
989-1017.
61